IHC 2021 | Progress in headache treatment & novel therapeutic targets

Anna Andreou, PhD, King’s College London, London, UK, talks on the positive progress of headache treatment, particularly migraine, in the last decade with the development of CGRP monoclonal antibodies and the advancement in the CGRP antagonists. However, Dr Andreou highlights that although many patients have found those treatments effective, others still did not respond as well. Therefore, novel treatments may be needed in migraine. Regarding other headache disorders, such as cluster headache, for which galcanezumab has been approved, there is also a need for novel therapeutic targets. This interview took place during the International Headache Congress 2021.